U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H17N3O4S
Molecular Weight 299.346
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMIPENEM ANHYDROUS

SMILES

[H][C@]12CC(SCCNC=N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

InChI

InChIKey=ZSKVGTPCRGIANV-ZXFLCMHBSA-N
InChI=1S/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1

HIDE SMILES / InChI
Molecular Formula C12H17N3O4S
Molecular Weight 299.346
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation. The bactericidal activity of imipenem results from the inhibition of cell wall synthesis. Its greatest affinity is for penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of Escherichia coli, and 1A, 1B, 2, 4 and 5 of Pseudomonas aeruginosa. The lethal effect is related to binding to PBP 2 and PBP 1B. Imipenem is marketed under the brand name Primaxin. PRIMAXIN I.M. (Imipenem and Cilastatin for Injectable Suspension) is a formulation of imipenem (a thienamycin antibiotic) and cilastatin sodium (the inhibitor of the renal dipeptidase, dehydropeptidase I). PRIMAXIN I.M. is a potent broad spectrum antibacterial agent for intramuscular administration.

Originator

Merck
236
Curator's Comment: Developed in 1980 by Merck # Merck

Approval Year

1985
114
Targets

Targets

Primary TargetPharmacologyConditionPotency
Penicillin-binding protein 1A
45
Target ID: P02918
Gene ID: 947907.0
Gene Symbol: mrcA
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
Penicillin-binding protein 1B
21
Target ID: P02919
Gene ID: 944843.0
Gene Symbol: mrcB
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
Penicillin-binding protein 2
24
Target ID: P0AD65
Gene ID: 945240.0
Gene Symbol: mrdA
Target Organism: Escherichia coli (strain K12)
Inhibitor
8228
Inhibitor
8228
Inhibitor
8228
Inhibitor
8228
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8360
PRIMAXIN

Approved Use

Imipenem and Cilastatin for Injection, USP (I.V.) is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Lower respiratory tract infections. Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzaeEfficacy for this organism in this organ system was studied in fewer than 10 infections. , Klebsiella species, Serratia marcescens Urinary tract infections (complicated and uncomplicated). Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii , Proteus vulgaris , Providencia rettgeri , Pseudomonas aeruginosa Intra-abdominal infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii , Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis, Fusobacterium species Gynecologic infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species, Escherichia coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis Bacterial septicemia. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species including B. fragilis Bone and joint infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa Skin and skin structure infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri , Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species Endocarditis. Staphylococcus aureus (penicillinase-producing strains) Polymicrobic infections. Imipenem and Cilastatin for Injection, USP (I.V.) is indicated for polymicrobic infections including those in which S. pneumoniae (pneumonia, septicemia), S. pyogenes (skin and skin structure), or nonpenicillinase-producing S. aureus is one of the causative organisms. However, monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G. Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established. For Pediatric Use information, see PRECAUTIONS, Pediatric Use, and DOSAGE AND ADMINISTRATION sections. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, Imipenem and Cilastatin for Injection, USP (I.V.) is useful for the treatment of mixed infections and as presumptive therapy prior to the identification of the causative organisms. Although clinical improvement has been observed in patients with cystic fibrosis, chronic pulmonary disease, and lower respiratory tract infections caused by Pseudomonas aeruginosa, bacterial eradication may not necessarily be achieved. As with other beta-lactam antibiotics, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Imipenem and Cilastatin for Injection, USP (I.V.). During therapy of Pseudomonas aeruginosa infections, periodic susceptibility testing should be done when clinically appropriate. Infections resistant to other antibiotics, for example, cephalosporins, penicillin, and aminoglycosides, have been shown to respond to treatment with Imipenem and Cilastatin for Injection, USP (I.V.). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

5.01811184E11
Curative
Approved
8360
PRIMAXIN

Approved Use

PRIMAXIN I.V. is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: (1) Lower respiratory tract infections. Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae*, Klebsiella species, Serratia marcescens (2) Urinary tract infections (complicated and uncomplicated). Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus vulgaris*, Providencia rettgeri*, Pseudomonas aeruginosa (3) Intra-abdominal infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis, Fusobacterium species (4) Gynecologic infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species*, Escherichia coli, Gardnerella vaginalis, Klebsiella species*, Proteus species, Bifidobacterium species*, Peptococcus species*, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis* (5) Bacterial septicemia. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species*, Bacteroides species including B. fragilis* (6) Bone and joint infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa (7) Skin and skin structure infections. Enterococcus faecalis, Staphylococcus aureus (penicillinaseproducing strains), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri*, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species* (8) Endocarditis. Staphylococcus aureus (penicillinase-producing strains) (9) Polymicrobic infections. PRIMAXIN I.V. is indicated for polymicrobic infections including those in which S. pneumoniae (pneumonia, septicemia), S. pyogenes (skin and skin structure), or nonpenicillinase-producing S. aureus is one of the causative organisms. However, monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G. PRIMAXIN I.V. is not indicated in patients with meningitis because safety and efficacy have not been established.

Launch Date

5.01811184E11
Curative
Approved
8360
PRIMAXIN

Approved Use

PRIMAXIN I.V. is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: (1) Lower respiratory tract infections. Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae*, Klebsiella species, Serratia marcescens (2) Urinary tract infections (complicated and uncomplicated). Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus vulgaris*, Providencia rettgeri*, Pseudomonas aeruginosa (3) Intra-abdominal infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis, Fusobacterium species (4) Gynecologic infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species*, Escherichia coli, Gardnerella vaginalis, Klebsiella species*, Proteus species, Bifidobacterium species*, Peptococcus species*, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis* (5) Bacterial septicemia. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species*, Bacteroides species including B. fragilis* (6) Bone and joint infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa (7) Skin and skin structure infections. Enterococcus faecalis, Staphylococcus aureus (penicillinaseproducing strains), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri*, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species* (8) Endocarditis. Staphylococcus aureus (penicillinase-producing strains) (9) Polymicrobic infections. PRIMAXIN I.V. is indicated for polymicrobic infections including those in which S. pneumoniae (pneumonia, septicemia), S. pyogenes (skin and skin structure), or nonpenicillinase-producing S. aureus is one of the causative organisms. However, monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G. PRIMAXIN I.V. is not indicated in patients with meningitis because safety and efficacy have not been established.

Launch Date

5.01811184E11
Curative
Approved
8360
PRIMAXIN

Approved Use

PRIMAXIN I.V. is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: (1) Lower respiratory tract infections. Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae*, Klebsiella species, Serratia marcescens (2) Urinary tract infections (complicated and uncomplicated). Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus vulgaris*, Providencia rettgeri*, Pseudomonas aeruginosa (3) Intra-abdominal infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis, Fusobacterium species (4) Gynecologic infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species*, Escherichia coli, Gardnerella vaginalis, Klebsiella species*, Proteus species, Bifidobacterium species*, Peptococcus species*, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis* (5) Bacterial septicemia. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species*, Bacteroides species including B. fragilis* (6) Bone and joint infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa (7) Skin and skin structure infections. Enterococcus faecalis, Staphylococcus aureus (penicillinaseproducing strains), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri*, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species* (8) Endocarditis. Staphylococcus aureus (penicillinase-producing strains) (9) Polymicrobic infections. PRIMAXIN I.V. is indicated for polymicrobic infections including those in which S. pneumoniae (pneumonia, septicemia), S. pyogenes (skin and skin structure), or nonpenicillinase-producing S. aureus is one of the causative organisms. However, monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G. PRIMAXIN I.V. is not indicated in patients with meningitis because safety and efficacy have not been established.

Launch Date

5.01811184E11
Curative
Approved
8360
PRIMAXIN

Approved Use

Imipenem and Cilastatin for Injection, USP (I.V.) is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Lower respiratory tract infections. Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzaeEfficacy for this organism in this organ system was studied in fewer than 10 infections. , Klebsiella species, Serratia marcescens Urinary tract infections (complicated and uncomplicated). Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii , Proteus vulgaris , Providencia rettgeri , Pseudomonas aeruginosa Intra-abdominal infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii , Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis, Fusobacterium species Gynecologic infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species, Escherichia coli, Gardnerella vaginalis, Klebsiella species, Proteus species, Bifidobacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species, Bacteroides species including B. fragilis Bacterial septicemia. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species, Bacteroides species including B. fragilis Bone and joint infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa Skin and skin structure infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri , Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species Endocarditis. Staphylococcus aureus (penicillinase-producing strains) Polymicrobic infections. Imipenem and Cilastatin for Injection, USP (I.V.) is indicated for polymicrobic infections including those in which S. pneumoniae (pneumonia, septicemia), S. pyogenes (skin and skin structure), or nonpenicillinase-producing S. aureus is one of the causative organisms. However, monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G. Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established. For Pediatric Use information, see PRECAUTIONS, Pediatric Use, and DOSAGE AND ADMINISTRATION sections. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, Imipenem and Cilastatin for Injection, USP (I.V.) is useful for the treatment of mixed infections and as presumptive therapy prior to the identification of the causative organisms. Although clinical improvement has been observed in patients with cystic fibrosis, chronic pulmonary disease, and lower respiratory tract infections caused by Pseudomonas aeruginosa, bacterial eradication may not necessarily be achieved. As with other beta-lactam antibiotics, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with Imipenem and Cilastatin for Injection, USP (I.V.). During therapy of Pseudomonas aeruginosa infections, periodic susceptibility testing should be done when clinically appropriate. Infections resistant to other antibiotics, for example, cephalosporins, penicillin, and aminoglycosides, have been shown to respond to treatment with Imipenem and Cilastatin for Injection, USP (I.V.). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

5.01811184E11
Curative
Approved
8360
PRIMAXIN

Approved Use

PRIMAXIN I.V. is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: (1) Lower respiratory tract infections. Staphylococcus aureus (penicillinase-producing strains), Acinetobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae*, Klebsiella species, Serratia marcescens (2) Urinary tract infections (complicated and uncomplicated). Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus vulgaris*, Providencia rettgeri*, Pseudomonas aeruginosa (3) Intra-abdominal infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii*, Proteus species, Pseudomonas aeruginosa, Bifidobacterium species, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis, Fusobacterium species (4) Gynecologic infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains)*, Staphylococcus epidermidis, Streptococcus agalactiae (Group B streptococci), Enterobacter species*, Escherichia coli, Gardnerella vaginalis, Klebsiella species*, Proteus species, Bifidobacterium species*, Peptococcus species*, Peptostreptococcus species, Propionibacterium species*, Bacteroides species including B. fragilis* (5) Bacterial septicemia. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter species, Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Serratia species*, Bacteroides species including B. fragilis* (6) Bone and joint infections. Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter species, Pseudomonas aeruginosa (7) Skin and skin structure infections. Enterococcus faecalis, Staphylococcus aureus (penicillinaseproducing strains), Staphylococcus epidermidis, Acinetobacter species, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Morganella morganii, Proteus vulgaris, Providencia rettgeri*, Pseudomonas aeruginosa, Serratia species, Peptococcus species, Peptostreptococcus species, Bacteroides species including B. fragilis, Fusobacterium species* (8) Endocarditis. Staphylococcus aureus (penicillinase-producing strains) (9) Polymicrobic infections. PRIMAXIN I.V. is indicated for polymicrobic infections including those in which S. pneumoniae (pneumonia, septicemia), S. pyogenes (skin and skin structure), or nonpenicillinase-producing S. aureus is one of the causative organisms. However, monobacterial infections due to these organisms are usually treated with narrower spectrum antibiotics, such as penicillin G. PRIMAXIN I.V. is not indicated in patients with meningitis because safety and efficacy have not been established.

Launch Date

5.01811184E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.86 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31124013
0.5 g 4 times / day multiple, oral
dose: 0.5 g
route of administration: Oral
experiment type: MULTIPLE
co-administered: CILASTATIN
CILASTATIN
 IMIPENEM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
48.43 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31124013
0.5 g 4 times / day multiple, oral
dose: 0.5 g
route of administration: Oral
experiment type: MULTIPLE
co-administered: CILASTATIN
CILASTATIN
 IMIPENEM blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
28.17 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31124013
0.5 g 4 times / day multiple, oral
dose: 0.5 g
route of administration: Oral
experiment type: MULTIPLE
co-administered: CILASTATIN
CILASTATIN
 IMIPENEM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.7 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6583194
250 mg 1 times / week other, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: OTHER
co-administered:
IMIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
36.5 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6583194
500 mg 1 times / week other, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: OTHER
co-administered:
IMIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.28 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31124013
0.5 g 4 times / day multiple, oral
dose: 0.5 g
route of administration: Oral
experiment type: MULTIPLE
co-administered: CILASTATIN
CILASTATIN
 IMIPENEM blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6583194
250 mg 1 times / week other, intravenous
dose: 250 mg
route of administration: Intravenous
experiment type: OTHER
co-administered:
IMIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/6583194
500 mg 1 times / week other, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: OTHER
co-administered:
IMIPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Other AEs: Diarrhea, Convulsions...
Other AEs:
Diarrhea (3%)
Convulsions (5.9%)
Tachycardia (1.5%)
Skin rash (1.5%)
Candidiasis (1.5%)
Oliguria and anuria (2.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Other AEs: Phlebitis, Infusion site irritation...
Other AEs:
Phlebitis (2.2%)
Infusion site irritation (1.1%)
Diarrhea (3.9%)
Gastroenteritis (1.1%)
Vomiting (1.1%)
Skin rash (2.2%)
Discoloration urine (1.1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
unhealthy, adult
n = 2516
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 2516
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
Other AEs: Infusion site reaction, Nausea and vomiting...
Other AEs:
Infusion site reaction (5%)
Nausea and vomiting (4%)
Diarrhea (3%)
Drug fever (2.7%)
Seizures (1.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Other AEs: Thrombophlebitis, Injection site pain...
Other AEs:
Thrombophlebitis (3.1%)
Injection site pain (0.7%)
Injection site erythema (0.4%)
Induration (0.2%)
Nausea (2%)
Diarrhea (1.8%)
Vomiting (1.5%)
Skin rash (0.9%)
Pruritus (0.3%)
Urticaria (0.2%)
Hypotension (0.4%)
Fever (0.5%)
Seizures (0.4%)
Dizziness (0.3%)
Somnolence (0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Candidiasis 1.5%
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Skin rash 1.5%
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Tachycardia 1.5%
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Oliguria and anuria 2.2%
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Diarrhea 3%
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Convulsions 5.9%
15 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 15 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 15 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, 0 - 3 Months
n = 135
Health Status: unhealthy
Condition: infections
Age Group: 0 - 3 Months
Sex: unknown
Population Size: 135
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Discoloration urine 1.1%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Gastroenteritis 1.1%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Infusion site irritation 1.1%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Vomiting 1.1%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Phlebitis 2.2%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Skin rash 2.2%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Diarrhea 3.9%
25 mg/kg 4 times / day steady, intravenous
Recommended
Dose: 25 mg/kg, 4 times / day
Route: intravenous
Route: steady
Dose: 25 mg/kg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, > 3 Months
n = 178
Health Status: unhealthy
Condition: infections
Age Group: > 3 Months
Sex: unknown
Population Size: 178
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Seizures 1.5%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
unhealthy, adult
n = 2516
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 2516
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
Drug fever 2.7%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
unhealthy, adult
n = 2516
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 2516
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
Diarrhea 3%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
unhealthy, adult
n = 2516
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 2516
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
Nausea and vomiting 4%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
unhealthy, adult
n = 2516
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 2516
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
Infusion site reaction 5%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
unhealthy, adult
n = 2516
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 2516
Sources:
https://pubmed.ncbi.nlm.nih.gov/1921491/
Induration 0.2%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Somnolence 0.2%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Urticaria 0.2%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Dizziness 0.3%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Pruritus 0.3%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Hypotension 0.4%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Injection site erythema 0.4%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Seizures 0.4%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Fever 0.5%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Injection site pain 0.7%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Skin rash 0.9%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Vomiting 1.5%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Diarrhea 1.8%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Nausea 2%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Thrombophlebitis 3.1%
500 mg 4 times / day steady, intravenous
Recommended
Dose: 500 mg, 4 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 4 times / day
Co-administed with::
CILASTATIN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
unhealthy, adult
n = 1723
Health Status: unhealthy
Condition: infections
Age Group: adult
Sex: unknown
Population Size: 1723
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0090
http://www.3bsc.com/index/pro_info.php?id=19446
AA Blocks
AA00IB9D
https://www.aablocks.com/goods/Goods/detail?id=AA00IB9D
AHH Chemical co.,ltd
API-1080
http://www.ahhchemical.com/product/API-1080.html
AHH Chemical co.,ltd
MT-52801
http://www.ahhchemical.com/product/MT-52801.html
AHH Chemical co.,ltd
MT-52802
http://www.ahhchemical.com/product/MT-52802.html
Aaron Chemicals
AR00IC15
http://www.aaronchem.com/64221-86-9
Achemtek
0104-014325
http://www.achemtek.com/64221-86-9
AstaTech, Inc.
45200
http://www.astatechinc.com/CPSResult.php?CRNO=1392
Aurum Pharmatech LLC
X-2302
http://www.Aurumpharmatech.com/Product/ProductDetails/X_2302
AvaChem Scientific
1720
http://www.avachem.com/productSearch.asp?1720
BLD Pharm
BD134490
http://www.bldpharm.com/products/64221-86-9.html
BioChemPartner
BCP13012
http://www.biochempartner.com/442847-66-7-BCP13012
Boerchem
BC209124
http://www.boerchem.com/?product_35437.html
ChemMol
30108981
http://www.chemmol.com/chemmol/30108981.html
ChemMol
44003519
http://www.chemmol.com/chemmol/44003519.html
ChemMol
97602822
http://www.chemmol.com/chemmol/97602822.html
ChemMol
99091897
http://www.chemmol.com/chemmol/99091897.html
Chemenu
CM129216
http://www.chemenu.com/products/CM129216
Chemspace
CSSB00016990768
https://chem-space.com/CSSB00016990768
DC Chemicals
DC21292
http://www.dcchemicals.com/product_show-DC21292.html
Hairui
HR122373
http://www.hairuichem.com/en/product/64221-86-9.html
Hairui
HR132016
http://www.hairuichem.com/en/product/74431-23-5.html
Lab Network
LN01321996
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01321996
OChem
6046
http://www.ocheminc.com/index.php?act=psearch&pid=847I667
Smolecule
S591334
https://www.smolecule.com/products/s591334
THE BioTek
bt-310622
https://www.thebiotek.com/product/others/bt-310622
THE BioTek
bt-460826
https://www.thebiotek.com/product/others/bt-460826
Yuhao Chemical
HL4267
http://www.chemyuhao.com/64221-86-9.html
eNovation Chemicals
D962780
https://www.enovationchem.com/ProductDetails.asp?ProductID=D962780
iChemical
EBD805194
http://www.ichemical.com/products/64221-86-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Imipenem-induced seizure: a case of inappropriate, excessive, and prolonged surgical prophylaxis.
1993 Oct
Low convulsive activity of a new carbapenem antibiotic, DK-35C, as compared with existing congeners.
1999 Nov 5
Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan.
2001
Prevalence of penicillin-resistant Streptococcus pneumoniae in Kuwait.
2001 Apr
[Metallo-beta-lactamase producing bacteria].
2001 Apr
Antimicrobial susceptibility of potentially pathogenic halophilic vibrios isolated from seafood.
2001 Aug
Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase.
2001 Aug 24
Case-control study of risk factors for the development of enterococcal bacteremia.
2001 Feb
Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis.
2001 Feb
Two cases of diskitis attributable to anaerobic bacteria in children.
2001 Feb
Adhesion to a polymeric biomaterial affects the antibiotic resistance of Staphylococcus epidermidis.
2001 Jan
An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients.
2001 Jan
A clinical isolate of Bacteroides fragilis from Hungary with high-level resistance to imipenem.
2001 Jan
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age].
2001 Jan-Feb
Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).
2001 Jul
Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems.
2001 Jul
Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.
2001 Jul 30
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). III. Secular changes in susceptibility].
2001 Jun
A case of thoracic empyema due to suppurative melioidosis.
2001 Jun
Antibiotic susceptibility and phage typing of methicillin-resistant and -sensitive Staphylococcus aureus clinical isolates at three periods during 1991-1997.
2001 Jun
Blood stream infections in a medical intensive care unit: spectrum and antibiotic susceptibility pattern.
2001 Jun
Surveillance of bacterial resistance among isolates in Shanghai in 1999.
2001 Jun
Antibiotic resistance among Gram-negative non-fermentative bacteria at a teaching hospital in Saudi Arabia.
2001 Jun
Antimicrobial resistance surveillance of bacteria in 1999 in Korea with a special reference to resistance of enterococci to vancomycin and gram-negative bacilli to third generation cephalosporin, imipenem, and fluoroquinolone.
2001 Jun
A comparison of prophylactic antibiotic regimens against airborne orthopaedic wound contamination.
2001 Jun
A rare infection in a renal transplant recipient.
2001 Jun
Antifungal antibiotics and breakthrough bacteremias.
2001 Jun 1
Two-staged revision total hip arthroplasty due to Salmonella infection: case report.
2001 Mar
Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.
2001 Mar
Antimicrobial resistance from enterococci in a pediatric hospital. Plasmids in Enterococcus faecalis isolates with high-level gentamicin and streptomycin resistance.
2001 Mar-Apr
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution].
2001 May
Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
2001 May
Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients.
2001 Oct 1
Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus.
2001 Sep
Patents

Patents

06022885
5

Sample Use Guides

In Vivo Use Guide
PRIMAXIN I.M. (Imipenem and Cilastatin for Injection) is for intramuscular use only. Patients with lower respiratory tract infections, skin and skin structure infections, and gynecologic infections of mild to moderate severity may be treated with 500 mg or 750 mg administered every 12 hours depending on the severity of the infection. Intra-abdominal infection may be treated with 750 mg every 12 hours. Total daily IM dosages greater than 1500 mg per day are not recommended.
Route of Administration: Intramuscular
In Vitro Use Guide
The concentration of Imipenem that inhibited binding of radiolabeled [3H]penicillin to PBP 2a by 50% was 68 ug/ml
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:14:22 UTC 2023
Edited
by admin
on Wed Jul 05 23:14:22 UTC 2023
Record UNII
Q20IM7HE75
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IMIPENEM ANHYDROUS
Common Name English
Imipenem [WHO-DD]
Common Name English
imipenem [INN]
Common Name English
IMIPENEM, ANHYDROUS
Common Name English
ANHYDROUS IMIPENEM
Common Name English
IMIPENEM [MI]
Common Name English
IMIPENEM ANHYDRATE
Common Name English
1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 6-(1-HYDROXYETHYL)-3-((2-((IMINOMETHYL)AMINO)ETHYL)THIO)-7-OXO-, (5R-(5.ALPHA.,6.ALPHA.(R*)))-
Common Name English
(5R,6S)-3-((2-(FORMIMIDOYLAMINO)ETHYL)THIO)-6-((R)-1-HYDROXYETHYL)-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NCI_THESAURUS C260
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000175496
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
NDF-RT N0000011294
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
Code System Code Type Description
PUBCHEM
104838
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
EPA CompTox
DTXSID2023143
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
CAS
64221-86-9
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
INN
5181
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
FDA UNII
Q20IM7HE75
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
RXCUI
1545986
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
264-734-5
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
NCI_THESAURUS
C146984
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
EVMPD
SUB08151MIG
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
CHEBI
471744
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
EVMPD
SUB36981
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
DAILYMED
Q20IM7HE75
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
MERCK INDEX
M6231
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY Merck Index
SMS_ID
100000088153
Created by admin on Wed Jul 05 23:14:22 UTC 2023 , Edited by admin on Wed Jul 05 23:14:22 UTC 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of IMIPENEM
SUBSTANCE->BASIS OF STRENGTH
CARBAPENEM-HYDROLYZING BETA-LACTAMASE KPC
ENZYME->SUBSTRATE
Inactivates antibacterial activity
APICAL
Structure of IMIPENEM
SOLVATE->ANHYDROUS
Structure of IMIPENEM
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of IMIPENEM ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966